ESMOEuropean Society for Medical Oncology
ESMOEuropean Student Moon Orbiter
ESMOEarth Science Mission Operations
ESMOElectronic Service for Medical Offices (Sunrise, FL)
ESMOEssential Services Maintenance Ordinance (India)
ESMOExcited-State Molecular Orbital
References in periodicals archive ?
I think that is one of the most important pieces of news for patients at this ESMO meeting," said Fouad Namouni, Bristol-Myers's head of medical oncology development.
Results of Bristol's failed Opdivo trial, which included patients with tumours testing only 5 per cent or higher for PD-L1 against the 50 per cent cut-off used by Merck, were also presented at ESMO.
National governments must take urgent action to improve access to these medicines, said ESMO, with 22 partners that launched the first global survey to evaluate opioids availability and accessibility for cancer pain management.
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT).
D, CEO of Provectus said, "The protocol design presented at ESMO reflects guidance we've received during discussions with the FDA and the Australian Therapeutic Goods Association ("TGA") about our proposed Phase 3 trial for metastatic melanoma.
At the ESMO 2017 Congress, there will be an oral presentation on the results of a health-related Quality of Life analysis of patients from a Phase III clinical trial (REFLECT/Study 304) of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma, and a separate oral presentation on the results of an analysis of biomarkers from the same study.
LOS ANGELES -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma was presented today at the Sarcoma Poster-Discussion Session (Hall H) at the ESMO (European Society of Medical Oncology) 2012 Congress in Vienna, Austria.
The research is presented at ESMO 2017 Congress in Madrid, Spain.
As previously reported, the study did not achieve its primary endpoint; however, the results presented at ESMO suggest that the addition of ficlatuzumab to gefitinib may be effective in select subsets of patients.
M2 PHARMA-September 12, 2017-Zymeworks Presents Additional Data from Study of ZW25 at the ESMO 2017 Congress
The studies were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
The results are being presented this morning at the ESMO 2012 Congress of the European Society for Medical Oncology being held in Vienna, Austria.